Genelux Corporation Raises $20M in Public Offering

Genelux Corporation priced a $20 million underwritten public offering of 6.67 million shares of common stock at $3 per share. The net proceeds will be used for general corporate purposes, including research and development expenses, clinical trial expenses, capital expenditures, and working capital. The offering is expected to close on January 9, 2026, subject to customary closing conditions. Lucid Capital Markets is the sole book-running manager for the offering.